Expectations of life sciences companies today include faster innovation, transparent drug pricing, and a greater purpose beyond profits. Some companies are hunkering down to weather the current economic storm. However, leaders are rethinking their operating models to ensure they can meet stakeholder expectations, anticipate threats, and capitalize on data-driven insights to win in the marketplace.
In this paper, KPMG professionals examine four primary signals of change and four strategic imperatives that represent the future of life sciences.
